Taysha Gene Therapies
TSHA
Market cap $307M

1.50 USD

+0.08

5.63%

At close Nov 8, 4:00 PM EST

After hours

1.52

+0.02

1.33%

1 day

5.63%

5 days

-4.46%

1 month

-25.37%

3 months

-28.57%

6 months

-36.97%

Year to date

-12.28%

1 year

-33.92%

5 years

-93.77%

About: Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Employees: 52

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,759 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

110% more call options, than puts

Call options by funds: $208K | Put options by funds: $99K

23% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 22

1.75% more ownership

Funds ownership: 80.46% [Q1] → 82.22% (+1.75%) [Q2]

5% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 37

2% less funds holding

Funds holding: 107 [Q1] → 105 (-2) [Q2]

14% less capital invested

Capital invested by funds: $432M [Q1] → $371M (-$60.8M) [Q2]

67% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 1 (-2) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

300%

upside

Avg. target

$6.33

322%

upside

High target

$7

367%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Canaccord Genuity Whitney Ijem 47% 1-year accuracy 16 / 34 met price target	300%upside $6	Buy Maintained	14 Aug 2024
Chardan Capital Geulah Livshits 26% 1-year accuracy 8 / 31 met price target	367%upside $7	Buy Maintained	13 Aug 2024
Needham Gil Blum 43% 1-year accuracy 64 / 150 met price target	300%upside $6	Buy Maintained	12 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about TSHA published over the past 30 days

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 157,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Zacks Investment Research

Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why

Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Taysha Gene Therapies' TSHA-102 shows promising results for Rett syndrome, leveraging miRARE technology to modulate MECP2 expression, improving patients' quality of life in Phase 1/2 trials. TSHA-102's unique miRNA-responsive auto-regulatory feature ensures safe MECP2 levels, with intrathecal administration targeting CNS cells, minimizing systemic adverse effects. Despite recent stock price decline, TSHA has a solid cash runway and potential market, with key catalysts expected by late 2024 and 1H2025.

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 501,600 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 3, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 311,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

24/7 Wall Street

3 Penny Stocks to Buy With $100

Have you thought about adding penny stocks to your portfolio? You may be onto something. That is, as long as you choose the right stock picks. But there are risks to consider too.

3 Penny Stocks to Buy With $100

Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript

Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript

Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates

Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.38 per share a year ago.

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements across consistent clinical domains and an encouraging safety profile in adult (up to 52 weeks) and pediatric (up to 22 weeks) patients

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

See News Rankings

Charts implemented using Lightweight Charts™